Cargando…
Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626351/ https://www.ncbi.nlm.nih.gov/pubmed/36341185 http://dx.doi.org/10.1002/iju5.12538 |
| _version_ | 1784822712476106752 |
|---|---|
| author | Yuasa, Takeshi |
| author_facet | Yuasa, Takeshi |
| author_sort | Yuasa, Takeshi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9626351 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96263512022-11-03 Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab Yuasa, Takeshi IJU Case Rep Editorial Comment John Wiley and Sons Inc. 2022-09-20 /pmc/articles/PMC9626351/ /pubmed/36341185 http://dx.doi.org/10.1002/iju5.12538 Text en © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Editorial Comment Yuasa, Takeshi Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title | Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_full | Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_fullStr | Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_full_unstemmed | Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_short | Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_sort | editorial comment to a case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| topic | Editorial Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626351/ https://www.ncbi.nlm.nih.gov/pubmed/36341185 http://dx.doi.org/10.1002/iju5.12538 |
| work_keys_str_mv | AT yuasatakeshi editorialcommenttoacaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab |